Top 5 Drug Type | Count |
---|---|
Small molecule drug | 25 |
Gene editing | 4 |
Monoclonal antibody | 2 |
Proteolysis-targeting chimeras (PROTAC) | 2 |
Chemical drugs | 1 |
Target |
Mechanism TREK1 stimulators [+1] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism KDM5B agonists |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism Kv7.2 agonists |
Active Org. |
Originator Org. |
Active Indication- |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date01 Nov 2024 |
Sponsor / Collaborator |
Start Date01 Jul 2023 |
Sponsor / Collaborator |
Start Date10 May 2023 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
TW-1 (New York University Grossman School of Medicine) ( PRNP x TAU ) | Alzheimer Disease More | Preclinical |
WK500B ( BCL6 ) | Diffuse Large B-Cell Lymphoma More | Preclinical |
Bisnoralcohol ( RANKL ) | Osteoporosis More | Preclinical |
WJ-460 ( MYOF ) | Breast Cancer More | Preclinical |
MBM-17 ( NEK2 ) | Neoplasms More | Preclinical |